(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $2.22
发出时间: 14 Feb 2024 @ 22:33
回报率: -4.95%
上一信号: Feb 14 - 04:01
上一信号:
回报率: 1.14 %
Live Chart Being Loaded With Signals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...
Stats | |
---|---|
今日成交量 | 231 237 |
平均成交量 | 498 904 |
市值 | 188.91M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $-0.100 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.05 |
ATR14 | $0.00500 (0.24%) |
音量 相关性
Compugen Ltd 相关性 - 货币/商品
Compugen Ltd 财务报表
Annual | 2023 |
营收: | $33.46M |
毛利润: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2023 |
营收: | $33.46M |
毛利润: | $30.98M (92.59 %) |
EPS: | $-0.210 |
FY | 2022 |
营收: | $7.50M |
毛利润: | $6.53M (87.00 %) |
EPS: | $-0.390 |
FY | 2021 |
营收: | $6.00M |
毛利润: | $5.32M (88.67 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。